SCHEMBL4308482

SCHEMBL4308482

CCc1cc(C(=O)C(=O)c2cccc(Br)c2)ccc1OC(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.42
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
TSHR P16473 2/20 0.40
PDE4A P27815 3/20 0.40
PDE4B Q07343 3/20 0.40
PDE4C Q08493 3/20 0.40
PDE4D Q08499 3/20 0.40
PARP1 P09874 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 2/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4308571 0.85 CES2 (0.42) L3MBTL1KMT2AMEN1TSHRPDE4A
SCHEMBL4309787 0.83 L3MBTL1 (0.42) L3MBTL1KMT2AMEN1TSHRPDE4A
SCHEMBL4309868 0.81 BACE1 (0.38) KMT2AMEN1TSHRPDE4APDE4B
SCHEMBL4309772 0.80 ACACB (0.37) KMT2AMEN1TSHRPDE4APDE4B
SCHEMBL4306240 0.80 L3MBTL1 (0.42) L3MBTL1KMT2ATSHRKDM4ELMNA
SCHEMBL2792829 0.79 ALOX15 (0.51) L3MBTL1KMT2AMEN1TSHRPARP1
SCHEMBL2821243 0.79 CES2 (0.50) KMT2AMEN1PARP1KDM4ELMNA
SCHEMBL4306393 0.79 PDE4A (0.39) KMT2AMEN1PDE4APDE4BPDE4C
SCHEMBL27779818 0.77 TAAR1 (0.41) L3MBTL1PDE4APDE4BPDE4CPDE4D
SCHEMBL4304316 0.76 ACACB (0.41) L3MBTL1SMN1; SMN2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 EP disclosed
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS WYETH (US) 2009-02-12 US disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP L3MBTL1 3592/4885KMT2A 2465/4885MEN1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.